<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910139</url>
  </required_header>
  <id_info>
    <org_study_id>CP-001</org_study_id>
    <nct_id>NCT04910139</nct_id>
  </id_info>
  <brief_title>A User Study of the Soniflow System for Nasal Congestion Relief</brief_title>
  <official_title>A User Study of the Soniflow System for Nasal Congestion Relief</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Wave Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Wave Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Soniflow System consists of an acoustic vibrational headband paired with a Smartphone App&#xD;
      to provide rapid relief of nasal congestion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Soniflow System is a non-invasive device to provide rapid relief of nasal congestion. It&#xD;
      consists of a headband with ultrasound transducers (hardware) coupled to a Smartphone&#xD;
      application (software).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">November 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Nasal Symptom Score</measure>
    <time_frame>10 minutes</time_frame>
    <description>Total Nasal Symptom Score (TNSS), measured as sum of four symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing (using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe; with a possible TNSS of 0-12)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Nasal Symptom Score</measure>
    <time_frame>20 minutes</time_frame>
    <description>Total Nasal Symptom Score (TNSS), measured as sum of four symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing (using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe; with a possible TNSS of 0-12)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) for Headache</measure>
    <time_frame>10 minutes</time_frame>
    <description>Visual Analog Scale (VAS) for Headache, using a scale of 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) for Headache</measure>
    <time_frame>20 minutes</time_frame>
    <description>Visual Analog Scale (VAS) for Headache, using a scale of 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) for Facial Pain</measure>
    <time_frame>10 minutes</time_frame>
    <description>Visual Analog Scale (VAS) for Facial Pain, using a scale of 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) for Facial Pain</measure>
    <time_frame>20 minutes</time_frame>
    <description>Visual Analog Scale (VAS) for Facial Pain, using a scale of 0-10</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Nasal Congestion</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment using acoustic energy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Soniflow System</intervention_name>
    <description>Treatment using acoustic vibrational headband worn circumferentially at the level of the forehead paired with a Smartphone App.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Soniflow System to provide nasal congestion relief</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is &gt;18 years of age&#xD;
&#xD;
          2. Subject has had moderate to severe symptoms of nasal congestion for &gt;3 months (TNSS&#xD;
             rating of 2 or 3)&#xD;
&#xD;
          3. Subject has signed IRB-approved informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has neurologic comorbidities&#xD;
&#xD;
          2. Subject has active dental infection&#xD;
&#xD;
          3. Subject is pregnant&#xD;
&#xD;
          4. Subject has implanted intracranial electrostimulation device(s) (e.g. cochlear&#xD;
             implant, deep brain stimulator)&#xD;
&#xD;
          5. Subject has undergone sinonasal or craniomaxillofacial surgery within the lats 3&#xD;
             months&#xD;
&#xD;
          6. Subject has been diagnosed with intracranial hemorrhage within the last 6 months&#xD;
&#xD;
          7. Subject has open scalp wounds or rashes&#xD;
&#xD;
          8. Subject has any history of craniotomy without replacement of a bone flap&#xD;
&#xD;
          9. Subject has elevated sensitivity to sound&#xD;
&#xD;
         10. Any physical condition that in the investigator's opinion would prevent adequate study&#xD;
             participation or pose increased risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paramesh Gopi, Ph.D</last_name>
    <phone>3135098237</phone>
    <email>pgopi@3rdwavetherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Francisco Otolaryngology Medical Group</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Johnson, MD</last_name>
      <phone>415-362-5443</phone>
      <email>jjohnson@sfotomed.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 23, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

